Renaissance Technologies’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
PCM
ACM
FCM
BFS
LGP
CS
LCM
NCM
Renaissance Technologies's BMY.RT Position: Q4 2020 in Review
Renaissance Technologies sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 2,720,360 shares — an estimated $6.12M sold.
Renaissance Technologies first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $42.9M in Q4 2019. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.
- Renaissance Technologies reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
- Renaissance Technologies sold 2,720,360 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $6.12M.
- Renaissance Technologies first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
- Renaissance Technologies's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $42.9M in Q4 2019.
- 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.
Based on Renaissance Technologies's 13F filing for Q4 2020, filed 10 Feb 2021.